Nearly all cervical cancers are caused by persistent infection with certain high-risk types of human papillomavirus, or HPV. HPV is a large family of viruses, many of which cause no serious disease, while a smaller group has oncogenic potential. Infection can occur through intimate skin-to-skin contact involving the genital area and through vaginal, anal or oral sexual contact, as well as through shared sex toys. HPV infection is therefore common and does not imply promiscuity, infidelity or poor hygiene. The crucial causal distinction is that an HPV infection can be transient and harmless, whereas persistent infection with a high-risk type can cause cellular abnormalities that, over a prolonged period, may progress towards cervical cancer.
HPV causes cancer primarily through biological interference with the normal controls governing infected cells. Persistent high-risk HPV infection can produce viral proteins that disrupt cellular regulatory pathways responsible for controlling cell division, DNA-damage responses and programmed cell death. Over time, abnormal cells can accumulate additional genetic and epigenetic changes, allowing them to survive and proliferate inappropriately. The transformation is usually gradual rather than instantaneous. This explains why high-risk HPV detection does not mean that cancer already exists: most infections do not progress to cancer, and the immune system clears or suppresses many infections before significant cellular damage occurs.
The main additional factors associated with cervical-cancer risk generally influence the likelihood that a high-risk HPV infection will persist or progress. A weakened immune system, including immunosuppression associated with HIV or AIDS, can make persistent HPV infection and progression more likely. Smoking is another recognised risk factor because tobacco exposure can affect immune responses and expose cervical tissue to carcinogenic substances.
Having several children or having a first child at a young age has also been associated with increased risk, although such associations do not mean that pregnancy itself directly causes cervical cancer. Some previous cancers and certain historical prenatal exposures, such as maternal exposure to diethylstilbestrol, are also recognised in clinical risk assessment.
Long-term use of the combined oral contraceptive pill has been associated with a small increase in cervical-cancer risk, particularly with longer durations of use, although the relationship is complex and the absolute effect must be considered alongside the contraceptive pill's benefits and other health effects. This illustrates an important principle in cancer epidemiology: risk factors do not usually operate as simple one-to-one causes. A risk factor changes probability rather than determining an individual's outcome.
A person can develop cervical cancer without having every recognised risk factor, while many people with several risk factors never develop it. The overwhelming causal association with persistent high-risk HPV distinguishes cervical cancer from cancers for which no single infectious agent accounts for almost all cases.
Cervical cancer is not caused by ordinary sexual activity itself, and detecting HPV does not establish when or from whom the infection was acquired. HPV can remain undetected for a long period, and a positive result can represent a newly detectable infection or persistence of an infection acquired much earlier. Condoms reduce but do not eliminate HPV transmission because they do not cover every area of genital skin. HPV vaccination provides substantial protection against important cancer-causing HPV types but does not protect against every HPV type, so vaccinated people still benefit from cervical screening. These distinctions prevent common misunderstandings about causation, transmission and personal responsibility.
Prevention therefore targets the causal chain at several points. HPV vaccination reduces the probability of infection with important oncogenic HPV types, while cervical screening detects high-risk HPV and associated cellular abnormalities before invasive cancer develops. Smoking cessation removes an additional modifiable risk factor. Screening remains important after vaccination because vaccines do not cover every oncogenic HPV type and because vaccination does not reverse established infections. The combination of vaccination and screening is consequently more comprehensive than relying on either intervention alone.
At the cellular level, cervical carcinogenesis can be understood as the accumulation of abnormalities that progressively remove normal restraints on cell proliferation, survival and tissue invasion. Persistent high-risk HPV is the initiating or sustaining factor in nearly all cervical cancers, but tumour development requires additional biological events. Precancerous lesions may exhibit increasing cellular atypia and disorganisation without yet being invasive cancer. Some abnormal changes regress, some persist and some progress. This variable natural history explains why screening programmes do not simply label every abnormal cell as cancer and why follow-up and treatment decisions depend on the type and severity of the detected abnormality.
The most accurate answer to what causes cervical cancer is therefore that persistent infection with oncogenic HPV is the necessary central cause in nearly all cases, while host immunity, smoking, reproductive history, certain medical conditions and other factors influence the probability and rate of progression. HPV is necessary in the overwhelming majority of cases but is not sufficient by itself to guarantee cancer. The disease represents an interaction between viral persistence and changes in cervical cells over time. This understanding underpins modern prevention: preventing high-risk HPV infection, identifying persistent infection and treating precancerous changes can interrupt the pathway before invasive cervical cancer develops.
